Cost effectiveness of duloxetine compared with venlafaxine‐XR in the treatment of major depressive disorder

References

• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498–504
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO) homepage. Available from http://www.who.org [Accessed 26 Nov 2004]
   Google Scholar
• Chisholm D, Sanderson K, Ayuso-Mateos JL, et al. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry 2004;184: 393–403
   Google Scholar
• Murphy JM, Laird NM, Monson RR, et al. Incidence of depression in the Stirling County Study: historical and comparative perspectives. Psychol Med 2000;30:505–14
   PubMed Web of Science ®Google Scholar
• Parikh SV, Wasylenki D, Goering P, et al. Mood disorders: rural/urban differences in prevalence, health care utilization, and disability in Ontario. J Affect Disord 1996;38:57–65
   PubMed Web of Science ®Google Scholar
• Bland RC, Newman SC, Orn H. Period prevalence of psychiatric disorders in Edmonton. Acta Psychiatr Scand Suppl 1988; 338:33–42
   Google Scholar
• Bland RC, Orn H, Newman SC. Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatr Scand Suppl 1988;338:24–32
   Google Scholar
• Offord DR, Boyle MH, Campbell D, et al. One-year prevalence of psychiatric disorder in Ontarians 15 to 64 years of age. Can J Psychiatry 1996;41:559–63
   PubMed Web of Science ®Google Scholar
• Stephens T, Joubert N. The economic burden of mental health problems in Canada. Chronic Dis Can 2001;22:18–23
   PubMedGoogle Scholar
• Hemels ME, Koren G, Einarson TR. Increased use of antidepressants in Canada: 1981–2000. Ann Pharmacother 2002;36: 1375–9
   Google Scholar
• Kennedy S, Lam R, Cohen N, et al. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001;46:38S–58
   Google Scholar
• Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225–31
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389–99
   PubMed Web of Science ®Google Scholar
• Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457–70
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383–90
   PubMed Web of Science ®Google Scholar
• Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308–15
   PubMed Web of Science ®Google Scholar
• Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry 1997;58:393–8
   PubMed Web of Science ®Google Scholar
• Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999;56:171–81
   PubMed Web of Science ®Google Scholar
• Vis PMJ, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of MDD: a meta-analysis. Ann of Pharmacother 2005 [in press]
   Google Scholar
• Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 1997;12:286–96
   Google Scholar
• Statistics Canada homepage. Available from http://www.statcan.ca [Accessed 4 Jan 2005]
   Google Scholar
• Ontario Ministry of Health homepage. Ontario Drug Benefit Formulary. Available from http://www.health.gov.on.ca [Accessed 6 Jan 2005]
   Google Scholar
• Ontario Ministry of Health homepage. Schedule of benefits: physician services under the Health Insurance Act. Available from http://www.health.gov.on.ca [Accessed 5 Jan 2005]
   Google Scholar
• Hospital Statistics 91/92. Toronto: Ontario Ministry of Health. Dec 1, 1994
   Google Scholar
• Patented medicine Prices Review Board (PmPrB). Annual report 2003, figure 14. Available from http://www.pmprb-cepmb.gc.ca [Accessed 10 Jan 2005]
   Google Scholar
• Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 1997;19:559–69; discussion:538–9
   Google Scholar
• Anderson DR, O’Brien BJ, Levine MN, et al. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993;119:1105–12
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234–41
   Google Scholar
• Einarson TR, Arikian SR, Casciano J, et al. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999;21:296–308
   PubMed Web of Science ®Google Scholar
• Joffe RT, Iskedjian M, Einarson TR, et al. Examining the Saskatchewan health drug database for antidepressant use: the case of fluoxetine. Can J Clin Pharmacol 2001;8:146–52
   PubMedGoogle Scholar
• Reesal RT, Lam RW. Clinical guidelines for the treatment of depressive disorders. II. Principles of management. Can J Psychiatry 2001;46\(Suppl 1):21S–8
   Google Scholar
• Canadian Institute for Health Information (CIHI) homepage. Available from http://www.cihi.ca [Accessed 7 Jan 2005]
   Google Scholar
• IMS Health Canada homepage. Available from http://www.imshealthcanada.com [Accessed 26 Nov 2004]
   Google Scholar
• Entsuah R, Chitra R. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull 1997;33:671–6
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Mahe V, Haudiquet V, et al. Effectiveness of venlafaxine, extended release formulation, in the short-term and long-term treatment of generalized anxiety disorder: results of a survival analysis. J Clin Psychopharmacol 2002;22: 561–7
   PubMed Web of Science ®Google Scholar
• Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43–53
   PubMed Web of Science ®Google Scholar
• Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974–84
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110:697–706
   PubMed Web of Science ®Google Scholar
• Forssell H, Tasmuth T, Tenovuo O, et al. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain 2004;18:131–7
   PubMed Web of Science ®Google Scholar
• Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62:869–77
   Google Scholar
• Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396–404
   PubMed Web of Science ®Google Scholar
• Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166–74
   Google Scholar
• Lenox-Smith A, Conway P, Knight C. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmacoeconomics 2004;22:311–9
   Google Scholar